rivastigmine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 65 Diseases   14 Trials   14 Trials   1875 News 


«12...567891011121314151617»
  • ||||||||||  donepezil / Generic mfg.
    Clinical, Observational data, Journal:  Dementia Diagnoses and Treatment in Geriatric Ward Patients: A Cross-Sectional Study in Poland. (Pubmed Central) -  Mar 30, 2021   
    The results confirmed the high incidence of underdiagnoses and undertreatment of dementia in patients admitted to the geriatric ward. It is partly due to the lack of systematic cognitive assessment in primary care settings, although other factors can play a role.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Biomarker, Journal:  Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease. (Pubmed Central) -  Mar 13, 2021   
    Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance cholinergic neurotransmission as the first line of treatment against Alzheimer's disease (AD)...(i) The cholinergic system in AD, (ii) principles of AD PGx, (iii) PGx of Donepezil, Galantamine, Rivastigmine, Huperzine and other treatments, and (iv) practical recommendations...Defective variants may affect the clinical response to AChEIs. PGx geno-phenotyping is highly recommended prior to treatment.
  • ||||||||||  Journal:  Drugs for Parkinson's disease. (Pubmed Central) -  Mar 10, 2021   
    PGx geno-phenotyping is highly recommended prior to treatment. No abstract available
  • ||||||||||  donepezil / Generic mfg., rivastigmine / Generic mfg.
    PK/PD data, Journal:  Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats. (Pubmed Central) -  Mar 9, 2021   
    Maximum brain concentration after i.m. administration was reached in the 36 (8.34 ± 0.34 ng/mL) and 17 minute (6.18 ± 0.40 ng/mL), respectively for donepezil and rivastigmine. The differences in brain profile can be most easily expressed by plasma/brain AUC ratios: donepezil ratio in the brain was nine-times higher than in plasma and rivastigmine ratio was less than two-times higher than in plasma.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  The Association Between Frailty and Parkinson's Disease in the ReSPOnD Trial. (Pubmed Central) -  Mar 9, 2021   
    Data were collected as part of the double-blind randomised controlled rivastigmine to stabilise gait ReSPonD trial in 130 people with Hoehn and Yahr 2-3, idiopathic PD who had fallen in the year prior to enrolment...There was a high prevalence (84%) of pre-frail and frail individuals in patients participating in this RCT. Future research should determine the optimum tool to assess frailty in this at-risk population, and delineate the association between Parkinson's, frailty, and health outcomes.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Journal:  Therapeutic approaches to cholinergic deficiency in Lewy body diseases. (Pubmed Central) -  Feb 24, 2021   
    Targeting the basal forebrain with either deep brain stimulation (DBS) or cell-based therapies is another strategy to mitigate cortical cholinergic deficiency. Before NBM DBS studies continue, it will be important to resolve issues related to targeting, stimulation pattern, and duration.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Review, Journal:  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future? (Pubmed Central) -  Feb 13, 2021   
    Irreversible AChE inhibitors, with a long-acting mechanism of action, are inherently CNS selective and can more than double CNS AChE inhibition possible with short-acting inhibitors. Irreversible AChE inhibitors open the door to high-level CNS AChE inhibition and improved anti-neurodegenerative benefits that may be an important part of future treatments to more effectively prevent, delay the onset, or slow the progression of AD.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Assessment of Probiotics Mixture on Memory Function, Inflammation Markers, and Oxidative Stress in an Alzheimer's Disease Model of Rats. (Pubmed Central) -  Feb 5, 2021   
    In this study, 50 rats were allocated to five groups, namely control, sham, and AD groups with Aβ1-40 intra-hippocampal injection, as well as AD + rivastigmine and AD + probiotics groups with Aβ1-40 intra-hippocampal injection and 2 ml (1010 CFU) of probiotics (Lactobacillus reuteri, Lactobacillus rhamnosus, and Bifidobacterium infantis) orally once a day for 10 weeks...Besides, probiotics reduced IL-1β and TNF-α as inflammation markers in the AD model of rats. Our data revealed that probiotics are helpful in attenuating inflammation and oxidative stress in AD.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. (Pubmed Central) -  Feb 3, 2021   
    Our data revealed that probiotics are helpful in attenuating inflammation and oxidative stress in AD. The cognitive benefit from rivastigmine is larger in PDD patients with OH, possibly mediated by a direct antihypotensive effect.
  • ||||||||||  lamivudine HBV / Generic mfg.
    [VIRTUAL] Fanconi's Syndrome and Dementia in a Patient With Chronic Hepatitis B Taking Nucleoside/ Nucleotide Analogue (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_919;    
    Because of LAM resistance, adefovir dipivoxil 10mg qd (ADV) was added in Jul 2007...TDF was then switched to tenofovir alafenamide (TAF) 25mg qd in Mar 2019...He was given Sinemet 25/100 and rivastigmine by neurologist with some improvement...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    [VIRTUAL] Evaluation of Outpatient Dementia Medication Assessments at a Veterans Affairs Medical Center () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_858;    
    Collected data will be reviewed to evaluate if the Veteran had an appropriate provider and cognitive assessment within the past year. This data will help determine if there is a need for standardized monitoring of Veterans prescribed dementia medications at TVAMC.
  • ||||||||||  rivastigmine / Generic mfg., rasagiline / Generic mfg.
    [VIRTUAL] A NOVEL NEUROPROTECTIVE ANTI ALZHEIMER DRUG DERIVED FROM RIVASTIGMINE AND RASAGILINE (On Demand Symposia E) -  Dec 24, 2020 - Abstract #ADPD2021ADPD_839;    
    We have demonstrated that MT-031 exerted neuroprotective effect against H2O2-induced neurotoxicity and reactive oxygen species generation in human neuroblastoma SH-SY5Y cells and increase levels of BDNF, GDNF and NGF. We further investigated the anti-inflammatory and protective effects of MT-031 in scopolamine mouse model and inflammatory cell cultures.  Conclusions These findings provide evidence that MT-031 is a potent brain permeable novel multifunctional, neuroprotective and MAO-A/ChE/BuChE inhibitor, preserves beneficial properties of its parent drugs, rasagiline and rivastigmine, and thus is indicated as a novel therapeutic approach for AD.
  • ||||||||||  memantine / Generic mfg., rasagiline / Generic mfg.
    [VIRTUAL] COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE: NEURAL CORRELATES AND TREATMENT APPROACHES (On Demand Symposia B) -  Dec 24, 2020 - Abstract #ADPD2021ADPD_419;    
    Several drugs (e.g. rivastigmine, rasagiline, atomotoxetine) have been tested also in MCI-PD populations in small randomized placebo-controlled studies, however, without any conclusive positive results...Non-pharmacological interventions may be beneficial in distinct patient subgroups, including exercise, cognitive training, non-invasive brain stimulation methods, and other techniques to enhance angiogenesis, synaptic plasticity, and neurogenesis. Neuroprotective or disease-modifying drugs for treatment of mild cognitive impairment in PD or even for preclinical stages are awaited.
  • ||||||||||  yokukansan (TJ-54) / Tsumura
    Retrospective data, Review, Journal:  Pharmacologic interventions for prevention of delirium in hospitalized older people: A meta-analysis. (Pubmed Central) -  Dec 23, 2020   
    This meta-analysis suggests that dexmedetomidine is effective in reducing the incidence and duration of delirium in hospitalized older patients. Individual studies reveal effects of ramelteon, olanzapine and rivastigmine on the incidence of delirium but the evidence is insufficient to draw a robust conclusion.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to Scientific Assessment. (Pubmed Central) -  Dec 17, 2020   
    In the present article, the experimental and clinical evidence have been reviewed for various Indian herbal medicines such as Centella asiatica, Bacopa monnieri, Curcuma longa, Clitoria ternatea, Withania somnifera, Celastrus paniculatus, Evolvulus alsinoides, Desmodium gangeticum, Eclipta alba, Moringa oleifera and Convolvulus pluricaulis, which have shown potential in cognitive impairment. Some commonly available herbal formulations for memory impairment in India have also been reviewed.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Influence of a genetic variant of CHAT gene over the profile of plasma soluble ChAT in Alzheimer disease. (Pubmed Central) -  Dec 12, 2020   
    Moreover, AD patients homozygous for SNP rs1880676 A allele exhibited higher levels of ChAT activity. Considering this is the first study to report the influence of genetic variability of CHAT locus over ChAT activity in AD patients plasma, it opens a new set of important questions on peripheral cholinergic signaling in AD.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion, Trial completion date, Trial primary completion date:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Dec 8, 2020   
    P3,  N=721, Completed, 
    Considering this is the first study to report the influence of genetic variability of CHAT locus over ChAT activity in AD patients plasma, it opens a new set of important questions on peripheral cholinergic signaling in AD. Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020